Is kisqali used for early stage or metastatic breast cancer?

Is Kisqali approved for early-stage breast cancer?

Kisqali is approved in combination with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer in adults at high risk of recurrence. This approval came from the NATALEE trial, which showed a 25% relative risk reduction in invasive disease-free survival compared with endocrine therapy alone.

What does the NATALEE trial say about early-stage use?

The NATALEE trial enrolled patients with stage II and III hormone receptor-positive, HER2-negative breast cancer. It demonstrated consistent benefits across subgroups, including node-positive and node-negative cases. The three-year invasive disease-free survival rate reached 90.4% with Kisqali plus endocrine therapy versus 87.3% with endocrine therapy alone.

Can Kisqali be used in metastatic breast cancer?

Kisqali remains approved for first-line treatment of hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer in men and postmenopausal women, combined with an aromatase inhibitor. It also covers second-line use with fulvestrant in patients who progressed after endocrine therapy.

How does the early-stage indication differ from the metastatic indication?

The early-stage approval extends Kisqali's use beyond its original focus on advanced disease. The NATALEE trial data apply to patients who have had surgery and may include those with no visible remaining cancer, while the metastatic approval covers patients who have cancer that has spread beyond the local area.

What happens if someone has both early undiagnosed recurrence and metastatic breast cancer?

Patients who previously treated early-stage breast cancer and later develop metastases can still receive Kisqali based on the metastatic indication. This doppelganger case requires fresh hormone receptor and HER2 testing to confirm suitability.

When does Kisqali's patent expire?

Kisqali's patent expires in 2027 with additional exclusivity ending in 2030. The company has filed several additional patents that may extend protection beyond these dates.